Genentech Meets Primary Endpoint for Phase III Emicizumab Study

______________________________________________________________________________Note: The following is edited from a press release from Genentech. Read the full press release in it’s entirety here.Genentech, a member of the Roche Group, announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with hemophilia A and […]

Octapharma Presents Phase III NuProtect Data at 2016 ASH Annual Meeting

______________________________________________________________________________Note: The following is edited from a press release from Octapharma. Read the full press release in it’s entirety here.At the recent American Society of Hematology (ASH) Annual Meeting, Octapharma presented interim data from the ongoing phase 3 study, NuProtect. The NuProtect Study examines the immunogenicity, efficacy and safety of treatment with human cell-line derived recombinant FVIII (Nuwiq) in previously […]